Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs

Basit Öğe Kaydı
dc.authoridAlbayrak, Hulya/0000-0002-2022-578X
dc.contributor.authorAlbayrak, Hulya
dc.date.accessioned2024-10-29T17:59:23Z
dc.date.available2024-10-29T17:59:23Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBackground: Psoriasis is a chronic immune-mediated skin disease in which systemic inflammation plays an important role in its pathogenesis. In recent years, the neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were shown to be important indicators of inflammation. This study aimed to investigate the NLR, NMR, PLR, and SII levels in psoriasis patients treated with biological agents. Method: Clinical and biochemical data of 209 patients who received systemic therapy for psoriasis were obtained by retrospectively reviewing their medical records. The NLR, NMR, PLR, and SII values were calculated from the hemogram values of the patients. Results: In the third month of follow-up, the mean CRP, NLR, NMR, PLR, and SII values were significantly decreased compared with the baseline values. The SII values showed strong positive correlations with the NLR, NMR, and PLR. Adalimumab, etanercept, and infliximab, which are TNF-& alpha; blockers, were observed to be more effective on the PLR and NLR, and especially the NMR. Conclusions: The NLR, NMR, PLR, and SII, which are data derived from routine blood tests, can be used in the monitoring of the treatment of psoriasis, especially with TNF-& alpha; blockers.
dc.identifier.doi10.3390/jcm12175452
dc.identifier.issn2077-0383
dc.identifier.issue17en_US
dc.identifier.pmid37685519
dc.identifier.scopus2-s2.0-85170366612
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/jcm12175452
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14719
dc.identifier.volume12
dc.identifier.wosWOS:001061178300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectpsoriasis
dc.subjectneutrophil-ymphocyte ratio
dc.subjectplatelet-lymphocyte ratio
dc.subjectneutrophil-monocyte ratio
dc.subjectsystemic immune-inflammation index
dc.titleNeutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu